The latest results from the trial, which focused on patients with untreated, locally advanced or metastatic urothelial cancer, showed that the combination therapy reduced the risk of death by 49% compared to traditional chemotherapy.
With an additional 12 months of follow-up, the median overall was 33.8 months for the combination therapy, nearly double the 15.9 months for chemotherapy patients. The treatment also found a 52% reduction in disease progression or death.
The combination also demonstrated strong results in terms of response rates and duration, with 67.5% of patients having an objective response rate compared to 44.2% for chemotherapy.
